21 JUL 2023 | EU | CHMP adopts positive opinion for three biosimilars The Committee for Medicinal Products for Human...
BioBlast w/e 21 Jul 23
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Make priority your priority – ToolGen loses priority battle for CRISPR patent
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Trade Marked Goods Not ‘A Moveable Target’ in a Patent Claim
Australian and New Zealand patent examiners typically frown upon the use of trade marks in claims. Primarily, a trade...
BioBlast w/e 07 Jul 23
07 JUL 2023 | IN | CuraTeQ Biologics enters into exclusive licence agreement with BioFactura, Inc to commercialise its...
Good news for inventors of computer technologies – Perram J redefines manner of manufacture following Aristocrat
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
The $325M Question | Commonwealth Disappointed in Landmark Appeal Court Damages Case
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 30 Jun 23
01 JUL 2023 | US | Organon and Samsung Bioepis announce launch of Hadlima®, biosimilar to AbbVie’s Humira®...
BioBlast w/e 23 Jun 23
22 JUN 2023 | JP | ASLAN enters strategic licence with Zenyaku Kogyo to exclusively develop and commercialise novel...
BREAKING NEWS: COMMONWEALTH SANOFI DAMAGES DECISION DELIVERED BY FULL COURT: Sanofi avoids damages payment to the Commonwealth in Clopidogrel decision
The Full Federal Court handed down its decision this morning in the longstanding dispute as to whether the...
Cannabidiol PBS listing expanded: Chiesi secures second PBS reimbursed indication for Epidyolex®
The PBS listing for Chiesi’s Epidyolex®, an oral cannabidiol, was expanded on 1 June 2023 to include treatment of...
‘Selection’ amendments allowable before Patent Office in failed BioNTech opposition
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast f/e 16 Jun 23
16 JUN 2023 | BR | Bio-Thera Solutions enter agreement for distribution of BAT2206 (ustekinumab biosimilar to...
I’ll cry about it later – Katy Perry appeals AU trade mark loss
Katy Perry has appealed a Federal Court decision handed down on 21 April 2023 by Markovic J in Australia (Taylor v...
No issue estoppel in Australian Patent Office proceedings
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Use of a Trade Mark in Patent Claims not limited to the Trade Marked Goods so no Lack of Clarity
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 2 Jun 23
01 JUN 2023 | EU | New indication alert: EC approves Novartis’ Cosentyx® (secukinumab) for HS Novartis announced that...